Entasis Therapeutics Holdings Inc.
Entasis Therapeutics Holdings Inc. (ETTX): 3 pipeline candidates · ~8 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.7 months
D/E 1.65 · 0% dilution
Lead: Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for Entasis Therapeutics Holdings Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$33.5M
Quarterly Burn
$13.8M
Runway
7.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| etx0282cpdp | Phase 1 |
| etx0462 | Preclinical |
| sul-dur | Phase 3 |
Frequently asked questions
How many drug candidates are in Entasis Therapeutics Holdings Inc.'s pipeline?
Entasis Therapeutics Holdings Inc. (ETTX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Entasis Therapeutics Holdings Inc.'s lead drug candidate?
Entasis Therapeutics Holdings Inc.'s most advanced tracked candidate is etx0282cpdp (Phase 1) for complicated urinary tract infections (cUTIs).
What is Entasis Therapeutics Holdings Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Entasis Therapeutics Holdings Inc. has approximately 7.7 months of cash runway.
Who is the CEO of Entasis Therapeutics Holdings Inc.?
Manoussos Perros, Ph.D. is the chief executive officer of Entasis Therapeutics Holdings Inc. (ETTX).
Get the full picture on Entasis Therapeutics Holdings Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.